EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Defining Continuous Glucose Monitor Time in Range in a Large, Community-Based Cohort Without Diabetes

Nicole L Spartano iD, Naznin Sultana, Honghuang Lin, Huimin Cheng, Sophia Lu, David Fei, Joanne M Murabito, Maura E Walker, Howard A Wolpert, Devin W Steenkamp

The Journal of Clinical Endocrinology & Metabolism · 17.03.2025 · 110 (4) · 1128-1134

DOI: 10.1210/clinem/dgae626 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 11.09.2024. Verfasst von Nicole L Spartano und 9 weiteren Autor:innen. Beteiligte Einrichtung: Boston University's and National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA 01702, USA. Hauptthemen laut MEDLINE: Blood Glucose Self-Monitoring, Blood Glucose, Prediabetic State, Diabetes Mellitus. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NHLBI NIH HHS, Dexcom.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Continuous glucose monitor (CGM) companies are beginning to market these sensors to populations without diabetes, but the range of CGM values clinicians should expect to see for this population is unclear because there have been no large studies reporting these ranges.

Objective

This work aimed to report the physiological range of CGM time in range values observed across glycemic status, including individuals without diabetes, to serve as a reference for clinicians.

Methods

The Framingham Heart Study, a prospective cohort study, was conducted among community-dwelling adults with normoglycemia (n = 560), prediabetes (n = 463), and diabetes (n = 152). We conducted a cross-sectional investigation in participants who wore a Dexcom G6 Pro CGM (in blinded mode) for 7 or more complete days. Main outcome measures included CGM metrics including mean glucose and time spent in glucose ranges.

Results

Normoglycemic participants (mean age 58.5 years, 64.5% women, 93.3% non-Hispanic White) spent 87.0% time in the 70 to 140 mg/dL CGM range, and, on average, more than 15 minutes/day (1.2% time) at more than 180 mg/dL. Furthermore, normoglycemic participants spent approximately 3 hours/day (12.1% time) with CGM glucose at more than 140 mg/dL. On average, participants with prediabetes and diabetes spent 77.1% and 46.2% of time in the 70 to 140 mg/dL range, respectively.

Conclusion

Our results contribute to the understanding of the physiological CGM range in more than 1000 participants without diabetes. These results are also important for clinicians to reference as CGM sensors become more widely accessible to people without known diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood Glucose Self-MonitoringBlood GlucosePrediabetic StateDiabetes MellitusHumansFemaleMaleMiddle AgedCross-Sectional StudiesAgedProspective StudiesAdultCohort StudiesTime FactorsReference Values

Stichwörter der Autor:innen

continuous glucose monitoringepidemiologyglycemic traitsprediabetestechnology and diabetes

Substanzen

Blood Glucose

Autor:innen und Institutionen

  • Boston University's and National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA 01702, USA.
  • Section of Endocrinology, Diabetes, Nutrition, and Weight Management, Boston University Chobanian and Avedisian School of Medicine (BUCASM) and Boston Medical Center, Boston, MA 02118, USA.
  • Department of Biostatistics, Boston University School of Public Health (BUSPH), Boston, MA 02118, USA.
  • Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
  • Section of General Internal Medicine, Department of Medicine, BUCASM and Boston Medical Center, Boston, MA 02118, USA.
  • Department of Health Sciences, Sargent College of Health and Rehabilitation Sciences, Boston University, Boston, MA 02215, USA.

ORCID-Profile: Nicole L Spartano

Förderung

  • NIA NIH HHS
  • NHLBI NIH HHS
  • Dexcom
  • NIDDK NIH HHS
  • FHS's National Heart, Lung and Blood Institute
  • NIDDK

Zitieren

APA

Spartano, N. L., Sultana, N., Lin, H., Cheng, H., Lu, S., Fei, D., Murabito, J. M., Walker, M. E., Wolpert, H. A., & Steenkamp, D. W. (2025). Defining Continuous Glucose Monitor Time in Range in a Large, Community-Based Cohort Without Diabetes. The Journal of Clinical Endocrinology & Metabolism, 110(4), 1128-1134. https://doi.org/10.1210/clinem/dgae626

Vancouver

Spartano NL, Sultana N, Lin H, Cheng H, Lu S, Fei D, et al. Defining Continuous Glucose Monitor Time in Range in a Large, Community-Based Cohort Without Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2025;110(4):1128-1134. doi:10.1210/clinem/dgae626

BibTeX
@article{Spartano2025,
  author = {Spartano, Nicole L and Sultana, Naznin and Lin, Honghuang and Cheng, Huimin and Lu, Sophia and Fei, David and Murabito, Joanne M and Walker, Maura E and Wolpert, Howard A and Steenkamp, Devin W},
  title = {Defining Continuous Glucose Monitor Time in Range in a Large, Community-Based Cohort Without Diabetes},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {4},
  pages = {1128--1134},
  doi = {10.1210/clinem/dgae626}
}
Kostenlos starten →